Loading…
Loading…
FNCH (Finch Therapeutics Group, Inc.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
Finch Therapeutics Group, Inc. (NASDAQ: FNCH - Get Free Report) dropped 2.7% during trading on Wednesday. The stock traded as low as $12.50 and last traded at $12.50. Approximately 283 shares traded hands during mid-day trading, a decline of 82% from the average daily volume of 1,590 shares. The stock had previously closed at $12.85.
Risk and Volatility Eloxx Pharmaceuticals has a beta of -1720.35, suggesting that its share price is 172,135% less volatile than the S&P 500. Comparatively, Finch Therapeutics Group has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500. Profitability This table compares Eloxx Pharmaceuticals and Finch Therapeutics Group's
Profitability This table compares Finch Therapeutics Group and Eloxx Pharmaceuticals' net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Finch Therapeutics Group N/A -69.14% -26.92% Eloxx Pharmaceuticals N/A N/A N/A Earnings and Valuation This table compares Finch Therapeutics Group and Eloxx Pharmaceuticals"s revenue, earnings per share and
Earnings and Valuation This table compares Finch Therapeutics Group and ZIVO Bioscience"s top-line revenue, earnings per share and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Finch Therapeutics Group N/A N/A -$74.75 million ($8.82) -1.53 ZIVO Bioscience $15,850.00 2,464.05 -$7.78 million ($2.18) -4.55 ZIVO Bioscience has higher revenue and earnings than
ENDI Corp's shares rose significantly, driven by a substantial increase in AUM and a value-unlocking transaction, suggesting further upside potential. Finch Therapeutics awaits a post-trial decision that could significantly impact its share value, with a minimum award level already set. Nam Tai Property secured significant financing and sold a non-core property above appraisal value, indicating a potential closing of the gap between market price and fair value.
BOSTON, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (Nasdaq: FNCH) (“Finch” or the “Company”), a microbiome technology company with a portfolio of intellectual property and microbiome assets, today announced that it has provided notification to The Nasdaq Stock Market, LLC (“Nasdaq”) of its intent to delist the Company's common stock, par value $0.001 per share (the “Common Stock”), from the Nasdaq Global Select Market. Finch expects to file a Form 25 (Notification of Removal from Listing) with the Securities and Exchange Commission (the “SEC”) and Nasdaq relating to the delisting of its Common Stock on or about October 31, 2024.
Penny stocks to buy according to analysts. The post 4 Penny Stocks To Buy According To Analysts, Targets Up To 1,650% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Finch Therapeutics Group, Inc. (FNCH) delivered earnings and revenue surprises of -12.50% and 90.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
No recent filings indexed.